SGX Market Updates

Highlights of SGX’s Largest, Best-Performing Healthcare Services Stocks


PUBLISHED ON |

06 August 2019

  • Singapore’s healthcare sector is typically viewed as defensive, and poised to enjoy multi-year growth prospects. There are 19 healthcare service providers listed on SGX with a combined market capitalisation of more than S$20 billion, and they operate patient care services and facilities both in the city-state and globally. 

  • Over the 7M2019 period, the 10 largest healthcare services providers on SGX have averaged a total return of +5.7%. The 3 best performers among them were ISEC Healthcare (+45.2%), HMI (+34.1%) and Singapore O&G (+14.2%), averaging a total return of +31.2% over the period.

  • Across the region, healthcare spending is on the rise. The government anticipates Singapore's average annual healthcare spending to increase to almost 3% of GDP over the next decade from 2.2% currently. In Asia-Pacific, the healthcare market is forecast to expand by more than 7% to nearly US$500 billion this year, driven by the growth of smart hospitals, home care developments and medical tourism, according to Frost & Sullivan.




Defensive Sector

Singapore’s healthcare sector is typically viewed as a defensive segment, and poised to enjoy multi-year growth prospects. Drivers of Asia’s increased healthcare spending levels include accelerated ageing rates, the rise of lifestyle diseases like diabetes and hypertension, as well as growing disposable incomes. 

The listed healthcare sector in Singapore, as tracked by the benchmark iEdge SG All Healthcare Index, comprises companies that operate in the segments of pharmaceuticals and biotechnology, healthcare and patient services, as well as medical equipment and supplies.

There are 19 healthcare service providers listed on SGX – with a combined market capitalisation of about S$23 billion – that operate patient care services and facilities, both locally and worldwide. These facilities include laboratories, hospitals, nursing homes and clinics that offer services and treatments ranging from family medicine, dentistry, endoscopy and aesthetics to gynaecology, oncology, paediatrics, orthopaedics, ophthalmology and even cord blood banking.

The majority of Singapore’s healthcare service providers have also pursued international expansion plans in recent years. Their operations and assets span multiple geographies outside the city-state, including markets in South and Southeast Asia, Northeast Asia, as well as Middle East and Europe.

Investors can easily participate in the structural Asian healthcare theme through SGX-listed healthcare stocks that are rapidly expanding into regional and global markets to meet growing patient needs.



10 Largest Healthcare Services Plays

The 10 largest healthcare services providers on SGX have a combined market capitalisation of more than S$20 billion, and have averaged a total return of +5.7% over the first seven months of 2019. This brings their one-year and three-year total returns to -3.4% and +17.7% respectively.

The 3 best performers were ISEC Healthcare (+45.2%), Health Management International (+34.1%) and Singapore O&G (+14.2%), averaging a total return of +31.2% in 7M2019. This brings their one-year and three-year total returns to +22.7% and +42.2% respectively. The trio also averaged a dividend indicated yield of 3.3%.


The table below details the 10 largest healthcare services stocks on SGX, sorted by YTD total return.

Name SGX
Code
Market
Cap
S$m
Total
Return
YTD
%
Total
Return
1 Yr
%
Total
Return
3 Yr
%
P/E
(x)
Dividend
Ind Yield
%
ISEC HEALTHCARE 40T 181 45.2 26.7 36.1 21.2 4.5
HEALTH MGMT INTL 588 603 34.1 24.6 115.3 36.1 0.9
SINGAPORE O&G 1D8 186 14.2 16.8 -24.7 21.0 4.4
IHH HEALTHCARE Q0F 16,407 5.0 -5.1 -14.8 84.6 0.5
OUE LIPPO HEALTHCARE 5WA 280 -3.1 -33.3 26.3 NA NA
Q&M DENTAL GROUP QC7 377 -3.1 -9.6 -27.3 28.7 1.7
SINGAPORE MEDICAL GROUP 5OT 184 -3.8 -9.4 137.7 14.0 NA
RAFFLES MEDICAL GROUP BSL 1,883 -4.5 -5.8 -30.7 27.7 2.4
THOMSON MEDICAL GROUP A50 1,666 -13.4 -20.8 -49.3 NM 0.4
TALKMED GROUP 5G3 664 -14.1 -18.5 8.1 22.8 3.6
Average   5.7 -3.4 17.7

Source: Bloomberg & StockFacts (data as of 31 July 2019)



Robust Outlook

Across Asia and in Singapore, healthcare spending by governments is set to rise. When unveiling Singapore’s 2019 Budget in February, Finance Minister Heng Swee Keat said the city-state’s healthcare spending is expected to rise to S$11.7 billion in FY19 from S$10.6 billion the previous year, as the government increases patient subsidies while expanding clinical services and capacity.

The government has also estimated that Singapore’s average annual healthcare spending will increase to almost 3% of gross domestic product (GDP) over the next decade from 2.2% currently, reflecting a gain of nearly 0.8-percentage point of GDP.

In response to the growing medical needs of a rapidly ageing population, the government also unveiled a S$6.1 billion fund that will subsidise healthcare for nearly 500,000 Singaporeans born in the 1950s, called the Merdeka Generation Package.

Several hospitals in Singapore are also expected to open over the next five years, including Sengkang General and Community Hospital, Outram Community Hospital and Woodlands General Hospital. This will add 3,200 acute hospital beds and 1,050 community hospital beds. 

According to Frost & Sullivan, the Asia-Pacific healthcare market is expected to expand by 7.2% to US$486.7 billion this year, driven by the growth of smart hospitals, developments in the home care segment and medical tourism. In particular, emerging markets such as China, India and ASEAN are expected to offer high-growth opportunities, the research consultancy noted in a recently published report.







This article is provided by SGX My Gateway.



SGX My Gateway

SGX's investor education portal with market, product and investment information and events. Sign up now at sgx.com/mygateway to receive our investment updates and economic calendar.

This document is not intended for distribution to, or for use by or to be acted on by any person or entity located in any jurisdiction where such distribution, use or action would be contrary to applicable laws or regulations or would subject Singapore Exchange Limited (“SGX”) to any registration or licensing requirement. This document is not an offer or solicitation to buy or sell, nor financial advice or recommendation for any investment product. This document is for general circulation only. It does not address the specific investment objectives, financial situation or particular needs of any person. Advice should be sought from a financial adviser regarding the suitability of any investment product before investing or adopting any investment strategies. Use of and/or reliance on this document is entirely at the reader’s own risk. Further information on this investment product may be obtained from www.sgx.com. Investment products are subject to significant investment risks, including the possible loss of the principal amount invested. Past performance of investment products is not indicative of their future performance. Examples provided are for illustrative purposes only. While each of SGX and its affiliates (collectively, the SGX Group Companies) have taken reasonable care to ensure the accuracy and completeness of the information provided, each of the SGX Group Companies disclaims any and all guarantees, representations and warranties, expressed or implied, in relation to this document and shall not be responsible or liable (whether under contract, tort (including negligence) or otherwise) for any loss or damage of any kind (whether direct, indirect or consequential losses or other economic loss of any kind, including without limitation loss of profit, loss of reputation and loss of opportunity) suffered or incurred by any person due to any omission, error, inaccuracy, incompleteness, or otherwise, any reliance on such information, or arising from and/or in connection with this document. The information in this document may have been obtained via third party sources and which have not been independently verified by any SGX Group Company. No SGX Group Company endorses or shall be liable for the content of information provided by third parties. The SGX Group Companies may deal in investment products in the usual course of their business, and may be on the opposite side of any trades. SGX is an exempt financial adviser under the Financial Advisers Act (Cap. 110) of Singapore. The information in this document is subject to change without notice. This document shall not be reproduced, republished, uploaded, linked, posted, transmitted, adapted, copied, translated, modified, edited or otherwise displayed or distributed in any manner without SGX’s prior written consent.












Stock / REIT Search

Advertisement

Advertisement